News

Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: A randomised double-blind intervention study

Imoro Zeba Braimah ,Ernest Kenu ,Kwesi N. Amissah-Arthur ,Stephen Akafo ,Kwaku Oppong Kwarteng ,Winfried M. Amoaku| Published: October 24, 2019 ...

Cardiovascular disease implicated in rapid glaucoma progression

To further understand the systemic and ocular risk factors for rapid glaucoma progression, investigators examined a cohort of rapid and ...

Should we image all patients with third nerve palsy?

This retrospective, population-based study assessed the incidence and etiologies of acquired third nerve palsy among newly diagnosed patients. Study design ...

Discovery of new angiogenic factor may enhance treatment for retinal disease

Scientists from Massachusetts Eye and Ear have identified a new transcription factor involved in retinal neovascularization: Runt-related transcription factor 1 ...

Low-cost ziv-aflibercept appears safe for intraocular administration

A multicenter study adds evidence that intravitreal ziv-aflibercept, a low-cost formulation of aflibercept originally developed as a systemic chemotherapy agent, ...

Telemedicine screening confirms acute ROP is typically symmetrical

In this secondary analysis of the Telemedicine Approaches to Evaluating Acute-phase ROP (e-ROP) study, investigators examined the intereye agreement of ...

Early findings hint at safety, efficacy of stem-cell therapy for keratoconus

Β The growing field of autologous stem-cell therapy has set its sights on another potential ocular target: corneal dystrophies. A Spanish ...